期刊
MOLECULAR PHARMACEUTICS
卷 8, 期 4, 页码 1090-1099出版社
AMER CHEMICAL SOC
DOI: 10.1021/mp100402n
关键词
docetaxel; HPMA copolymer; prostate carcinoma; RGDfK; alpha(v)beta(3) integrin; DU-145 prostate cancer cell line; PC3 prostate cancer cell line; targeted drug delivery
资金
- National Institutes of Health [R01 EB007171]
- Utah Science Technology and Research (USTAR) initiative
N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymer-docetaxel-RGDfk conjugate was synthesized, characterized, and evaluated in vitro and in vivo in comparison with untargeted low and high molecular weight HPMA copolymer docetaxel conjugates. The targeted conjugate was designed to have a hydrodynamic diameter below renal threshold to allow elimination post treatment. All conjugates demonstrated the ability to inhibit the growth of DU14S and PC3 human prostate cancer cells and the HUVEC at low nanomolar concentrations. The targeted conjugate showed active binding to alpha(v)beta(3) integrins in both HUVEC and DU145 cells, whereas the untargeted conjugate demonstrated no evidence of specific binding. Efficacy at two concentrations (20 mg/kg and 40 mg/kg) was evaluated in nu/nu mice bearing DU145 tumor xenografts treated with a single dose of conjugates and compared with controls. RGDfK targeted and high molecular weight nontargeted conjugates exhibited the highest antitumor efficacy as evaluated by tumor regression. These results demonstrate that alpha(v)beta(3) integrin targeted polymeric conjugates with improved water solubility, reduced toxicity and ease of elimination post treatment in vivo are promising candidates for prostate cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据